摘要:
The invention encompasses the novel compound of Formula I as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
摘要:
Leached nanocrystalline materials having a high specific surface are particularly useful for storing hydrogen or as catalysts or electrocatalysts in the manufacture electrodes, especially for fuel cells. Such materials can be manufactured by preparing a nanocrystalline material consisting of a metastable composite or alloy of at least two different chemical elements. To be nanocrystalline, this material must have a crystalline structure with the grain size lower than 100 nm. Then, the so prepared nanocrystalline material can be subjected to a leaching treatment in order to eliminate partially or totally one of the elements of the composite or alloy. This leaching results in nanocrystalline materials having a porous structure and, thereby, the requested high specific surface.
摘要:
The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
摘要:
The invention encompasses the novel compound of Formula I useful in the treatment of diseases, including asthma, by raising the level of cyclic adenosine-3',5'-monophosphate (cAMP) through the inhibition of phosphodiesterase IV (PDE IV). ##STR1## The invention also encompasses certain pharmaceutical compositions and methods for treatment of diseases by inhibition of PDE IV, resulting in an elevation of cAMP, comprising the use of compounds of Formula I.